Tisdag 28 April | 14:31:32 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Pila Pharma on the preclinical results and the way forward
2026-04-28 12:15:00

Pila Pharma recently announced that the lack of weight loss in the company's preclinical obesity studies was likely due to low exposure rather than lack of efficacy. A new formulation appears to have hindered the uptake of the candidate XEN-D0501. BioStock contacted CEO Gustav Gram to discuss the latest analyses, the path forward towards a phase II clinical study, and the most important milestones for investors in 2026.

See the interview at biostock.se:
Pila Pharma on the preclinical results and the way forward

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden